Cogent Biosciences logo

Cogent BiosciencesNASDAQ: COGT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 March 2018

Next earnings report:

26 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.28 B
-6%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector
-27%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 20:20:00 GMT
$11.72+$0.23(+2.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

COGT Latest News

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
zacks.com28 June 2024 Sentiment: POSITIVE

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
globenewswire.com14 June 2024 Sentiment: POSITIVE

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
globenewswire.com23 May 2024 Sentiment: POSITIVE

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).

3 Lost Formula Stocks to Consider for the 2nd Half of 2023
GuruFocus07 July 2023 Sentiment: POSITIVE

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Cogent Biosciences Announces Participation at Upcoming Investor Conferences
GlobeNewsWire12 April 2023 Sentiment: NEGATIVE

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

What type of business is Cogent Biosciences?

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

What sector is Cogent Biosciences in?

Cogent Biosciences is in the Healthcare sector

What industry is Cogent Biosciences in?

Cogent Biosciences is in the Biotechnology industry

What country is Cogent Biosciences from?

Cogent Biosciences is headquartered in United States

When did Cogent Biosciences go public?

Cogent Biosciences initial public offering (IPO) was on 29 March 2018

What is Cogent Biosciences website?

https://www.cogentbio.com

Is Cogent Biosciences in the S&P 500?

No, Cogent Biosciences is not included in the S&P 500 index

Is Cogent Biosciences in the NASDAQ 100?

No, Cogent Biosciences is not included in the NASDAQ 100 index

Is Cogent Biosciences in the Dow Jones?

No, Cogent Biosciences is not included in the Dow Jones index

When was Cogent Biosciences the previous earnings report?

No data

When does Cogent Biosciences earnings report?

The next expected earnings date for Cogent Biosciences is 26 February 2025